Pancreatic Cancer Research

ResearcherShiga University of Medical ScienceActive in the last 2 years

Keitaro Sofue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6132-1623; OpenAlex author ID A5075875207. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2017: 2 papers · 2018: 3 papers · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 3 papers · 2025: none · 2026: 4 papers

Papers 18

  1. Improved Image Quality of Virtual Monochromatic Images with Deep Learning Image Reconstruction Algorithm on Dual-Energy CT in Patients with Pancreatic Ductal A… Co-author DOI 10.1007/s10278-025-01514-6↗
  2. Characteristics of ill-demarcated small pancreatic ductal adenocarcinoma on MRI: a multi-institutional retrospective cohort study. Co-author DOI 10.1007/s11604-026-02003-8↗
  3. Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study. Co-author DOI 10.1097/sla.0000000000007075↗
  4. Deep Learning Detection of Direct and Indirect Imaging Findings Associated with Pancreatic Cancer at Contrast-enhanced and Noncontrast CT. First author DOI 10.1148/radiol.253122↗
  5. Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study. Co-author DOI 10.1002/ueg2.12557↗
  6. Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. Co-author DOI 10.1007/s00535-024-02149-0↗
  7. Rim Enhancement on Contrast-Enhanced CT as a Predictor of Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/diagnostics14080782↗
  8. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-022-01939-8↗
  9. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… Co-author DOI 10.1007/s00535-023-02020-8↗
  10. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Co-author DOI 10.1038/s41598-023-38920-1↗
  11. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Co-author DOI 10.1245/s10434-023-13569-2↗
  12. Abbreviated Gadoxetic Acid-Enhanced MRI for the Detection of Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1002/jmri.28059↗
  13. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1245/s10434-022-11704-z↗
  14. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2017.12.007↗
  15. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2018.04.005↗
  16. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Ad… Co-author DOI 10.1245/s10434-017-6274-8↗
  17. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1097/mpa.0000000000000761↗
  18. Pancreatic ductal adenocarcinoma with inferior vena cava invasion: a report of three resected cases. Co-author DOI 10.1186/s40792-017-0348-5↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsuhiro Masuda · 13 shared papers, 2017–2026 · strength 1.71
  2. Hirochika Toyama · 13 shared papers, 2017–2024 · strength 1.53
  3. Arata Sakai · 10 shared papers, 2018–2026 · strength 1.40
  4. Takashi Kobayashi · 11 shared papers, 2017–2026 · strength 1.31
  5. Takumi Fukumoto · 12 shared papers, 2017–2026 · strength 1.29
  6. Masanori Gonda · 8 shared papers, 2022–2026 · strength 1.17
  7. Masahiro Tsujimae · 7 shared papers, 2022–2026 · strength 0.98
  8. Mika Miki · 6 shared papers, 2023–2026 · strength 0.95
  9. Yuzo Kodama · 7 shared papers, 2022–2024 · strength 0.93
  10. Takeru Yamaguchi · 4 shared papers, 2022–2026 · strength 0.89
  11. Shigeto Ashina · 6 shared papers, 2022–2026 · strength 0.81
  12. Tomoo Itoh · 6 shared papers, 2022–2024 · strength 0.78
  13. Takuya Ikegawa · 6 shared papers, 2018–2026 · strength 0.71
  14. Shigeto Masuda · 5 shared papers, 2022–2023 · strength 0.62
  15. Kohei Yamakawa · 5 shared papers, 2022–2023 · strength 0.62
  16. Shohei Abe · 5 shared papers, 2022–2023 · strength 0.62
  17. Takeshi Tanaka · 5 shared papers, 2022–2023 · strength 0.62
  18. Yoshiyuki Harada · 4 shared papers, 2023–2026 · strength 0.59
  19. Ryota Nakano · 4 shared papers, 2022–2024 · strength 0.55
  20. Takamichi Murakami · 3 shared papers, 2022–2026 · strength 0.54
  21. Mamoru Takenaka · 5 shared papers, 2017–2024 · strength 0.48
  22. Yoshihide Nanno · 3 shared papers, 2018–2026 · strength 0.40
  23. Takayuki Kodama · 2 shared papers, 2024–2026 · strength 0.40
  24. Takamichi Murakami · 1 shared paper, 2026 · strength 0.36
  25. Yuichi Hirata · 2 shared papers, 2024–2026 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.